TY - JOUR
T1 - Curcumae Rhizoma - combined with Sparganii Rhizoma in the treatment of liver cancer
T2 - Chemical analysis using UPLC-LTQ-Orbitrap MSn, network analysis, and experimental assessment
AU - Wei, Jing
AU - Wang, Xiaoping
AU - Dong, Ying
AU - Zhong, Xiangjian
AU - Ren, Xueyang
AU - Song, Ruolan
AU - Ma, Jiamu
AU - Yu, Axiang
AU - Fan, Qiqi
AU - Yao, Jianling
AU - Shan, Dongjie
AU - Lv, Fang
AU - Zheng, Yuan
AU - Deng, Qingyue
AU - Li, Xianxian
AU - He, Yingyu
AU - Fan, Shusheng
AU - Zhao, Chongjun
AU - Wang, Xiuhuan
AU - Yuan, Ruijuan
AU - She, Gaimei
N1 - Publisher Copyright:
Copyright © 2022 Wei, Wang, Dong, Zhong, Ren, Song, Ma, Yu, Fan, Yao, Shan, Lv, Zheng, Deng, Li, He, Fan, Zhao, Wang, Yuan and She.
PY - 2022/12/5
Y1 - 2022/12/5
N2 - Objective: Curcumae Rhizoma–Sparganii Rhizoma (CR-SR) is a traditional botanical drug pair that can promote blood circulation, remove blood stasis, and treat tumors in clinics. The aim of the present study was to investigate the therapeutic material basis and potential mechanisms of CR-SR, CR, and SR for the treatment of liver cancer. Method: The chemical profile analyses of CR-SR, CR, and SR were performed by molecular networking and UPLC-LTQ-Orbitrap MSn. The anti-liver cancer activities of CR-SR, CR, and SR were assessed by using a zebrafish xenograft model in vivo for the first time and detected by the HepG2 cell model in vitro. Combining the network analysis and molecular docking, real-time quantitative polymerase chain reaction (RT-qPCR) experiments were undertaken to further explore the mechanisms of CR-SR, CR, and SR for the treatment of liver cancer. Results: In total, 65 components were identified in CR-SR, CR, and SR. Based on the clusters of molecular networking, a total of 12 novel diarylheptanoids were identified from CR-SR and CR. By combining our results with information from the literature, 32 sesquiterpenoids and 21 cyclic dipeptides were identified from CR-SR, CR, and SR. The anti-liver cancer activities were observed in both the drug pair and the single botanical drugs in vitro and in vivo, and the order of activity was CR-SR > CR > SR. They could downregulate the expression of proto-oncogene tyrosine-protein kinase Src (SRC), epidermal growth factor receptor (EGFR), estrogen receptor-α (ESR1), prostaglandin endoperoxide synthase 2 (PTGS2), and amyloid precursor protein (APP). Conclusion: Taken together, the present study provided an experimental basis for the therapeutic material basis and potential molecular mechanisms of CR-SR, CR, and SR. This study provided a novel insight for objective clinical treatment of liver cancer.
AB - Objective: Curcumae Rhizoma–Sparganii Rhizoma (CR-SR) is a traditional botanical drug pair that can promote blood circulation, remove blood stasis, and treat tumors in clinics. The aim of the present study was to investigate the therapeutic material basis and potential mechanisms of CR-SR, CR, and SR for the treatment of liver cancer. Method: The chemical profile analyses of CR-SR, CR, and SR were performed by molecular networking and UPLC-LTQ-Orbitrap MSn. The anti-liver cancer activities of CR-SR, CR, and SR were assessed by using a zebrafish xenograft model in vivo for the first time and detected by the HepG2 cell model in vitro. Combining the network analysis and molecular docking, real-time quantitative polymerase chain reaction (RT-qPCR) experiments were undertaken to further explore the mechanisms of CR-SR, CR, and SR for the treatment of liver cancer. Results: In total, 65 components were identified in CR-SR, CR, and SR. Based on the clusters of molecular networking, a total of 12 novel diarylheptanoids were identified from CR-SR and CR. By combining our results with information from the literature, 32 sesquiterpenoids and 21 cyclic dipeptides were identified from CR-SR, CR, and SR. The anti-liver cancer activities were observed in both the drug pair and the single botanical drugs in vitro and in vivo, and the order of activity was CR-SR > CR > SR. They could downregulate the expression of proto-oncogene tyrosine-protein kinase Src (SRC), epidermal growth factor receptor (EGFR), estrogen receptor-α (ESR1), prostaglandin endoperoxide synthase 2 (PTGS2), and amyloid precursor protein (APP). Conclusion: Taken together, the present study provided an experimental basis for the therapeutic material basis and potential molecular mechanisms of CR-SR, CR, and SR. This study provided a novel insight for objective clinical treatment of liver cancer.
KW - Curcumae Rhizoma - Sparganii Rhizoma
KW - UPLC-LTQ-Orbitrap MS
KW - liver cancer
KW - molecular networking
KW - zebrafish xenograft model
UR - http://www.scopus.com/inward/record.url?scp=85148285282&partnerID=8YFLogxK
U2 - 10.3389/fphar.2022.1027687
DO - 10.3389/fphar.2022.1027687
M3 - Article
AN - SCOPUS:85148285282
SN - 1663-9812
VL - 13
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1027687
ER -
